These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 7850921)

  • 1. A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors.
    Weiss GR; Kuhn JG; Rizzo J; Smith LS; Rodriguez GI; Eckardt JR; Burris HA; Fields S; VanDenBerg K; von Hoff DD
    Cancer Chemother Pharmacol; 1995; 35(5):397-402. PubMed ID: 7850921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of intermittent infusion cladribine in patients with solid tumors.
    Kobayashi K; Vogelzang NJ; O'Brien SM; Schilsky RL; Vokes EE; Ratain MJ
    Cancer; 1994 Jul; 74(1):168-73. PubMed ID: 7911736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion.
    Tchekmedyian NS; Egorin MJ; Cohen BE; Kaplan RS; Poplin E; Aisner J
    Cancer Chemother Pharmacol; 1986; 18(1):33-8. PubMed ID: 3757157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor.
    Holen K; Saltz LB; Hollywood E; Burk K; Hanauske AR
    Invest New Drugs; 2008 Feb; 26(1):45-51. PubMed ID: 17924057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
    Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
    Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.
    Herben VM; ten Bokkel Huinink WW; Schot ME; Hudson I; Beijnen JH
    Anticancer Drugs; 1998 Jun; 9(5):411-8. PubMed ID: 9660538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
    Villalona-Calero MA; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt SG; Drengler R; Simmons C; Santabarbara P; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1999 Nov; 5(11):3369-78. PubMed ID: 10589747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
    Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
    Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion.
    Supko JG; Lynch TJ; Clark JW; Fram R; Allen LF; Velagapudi R; Kufe DW; Eder JP
    Cancer Chemother Pharmacol; 2000; 46(4):319-28. PubMed ID: 11052630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of Taxotere: five-day schedule.
    Pazdur R; Newman RA; Newman BM; Fuentes A; Benvenuto J; Bready B; Moore D; Jaiyesimi I; Vreeland F; Bayssas MM
    J Natl Cancer Inst; 1992 Dec; 84(23):1781-8. PubMed ID: 1359154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical and pharmacological study of merbarone.
    Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S
    Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion.
    O'Dwyer PJ; Laub PB; DeMaria D; Qian M; Reilly D; Giantonio B; Johnston AL; Wu EY; Bauman L; Clendeninn NJ; Gallo JM
    Clin Cancer Res; 1996 Oct; 2(10):1685-92. PubMed ID: 9816117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
    Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
    J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
    Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
    Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion.
    Leguizamo J; Quinn M; Takimoto CH; Liang MD; Ismail AS; Pang J; Dahut W; Grem JL
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):333-8. PubMed ID: 12819941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.